Physalin B attenuates liver fibrosis via suppressing LAP2 α-HDAC1 mediated deacetylation of GLI1 and hepatic stellate cell activation
Running Title: Physalin B attenuates liver fibrosis via suppressing deacetylation of GLI1
Xiaoyun Zhu, Shengtao Ye, Jie Li, Meihui Zhang, Yanqiu Zhang, Yingrong Leng, Ting Yang, Jianguang Luo, Xinlin Chen, Hao Zhang*, Lingyi Kong*
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China
* Correspondence to:
Hao Zhang, State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China. E-mail:zhanghao@cpu.edu.cn ;
Lingyi Kong, State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China. E-mail:cpu_lykong@126.com;
Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Funding: This work was supported by National Natural Science Foundation of China (No. 82074068, 81872889) and Natural Science Foundation of Jiangsu Province (BK20181332) to Hao Zhang. The Drug Innovation Major Project (2018ZX09711-001-007 and 2018ZX09735002-003), the “Double First-Class” University Project (CPU2018GF03) to Lingyi Kong.
Author contributions: HZ and XYZ conceived the study and participated in the overall design, supervision, and coordination of the study. XYZ designed and performed most experiments. STY, JL, MHZ participated in molecular and cellular biological experiments. YRL, TY, YQZ participated in animal studies. HZ and XYZ wrote the manuscript. LYK supervised the overall project. All authors read and approved the manuscript.
Acknowledgments: We cordially wish to acknowledge the cellular platform and the pathology center for the excellent technical support.
Conflicts of interest: The authors declare no conflicts of interest.
Ethicsapproval: All mice received human care and animal experiments were approved by the University Committee on Use and Care of Animals of the China Pharmaceutical University (Nanjing, China). (Approval NO.2020-0701)